Literature DB >> 18757286

Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma.

Erica C Henning1, Lawrence L Latour, John M Hallenbeck, Steven Warach.   

Abstract

BACKGROUND AND
PURPOSE: Symptomatic hemorrhagic transformation (HT) is the most important complicating factor after treatment with intravenous tissue plasminogen activator. In this study, we used multimodal magnetic resonance imaging to investigate the incidence and severity of reperfusion-based HT in spontaneously hypertensive rats after ischemia/reperfusion.
METHODS: Twenty male spontaneously hypertensive rats were subjected to 30 minutes of middle cerebral artery occlusion via the suture model. Diffusion-weighted, T(2)-weighted, and gradient-echo imaging were performed on days 1, 2, 3, 4, and 7 for longitudinal evaluation of lesion evolution, vasogenic edema, and HT, respectively. Findings on gradient-echo images were classified according to the severity of hemorrhage: no HT; punctate or small petechial hemorrhage (HI-1); confluent petechial hemorrhage (HI-2); hematoma with absent/mild space-occupying effect (PH-1, <or=30% lesion volume); and hematoma with significant space-occupying effect and potential perihematomal edema (PH-2, >30% lesion volume). Histopathologic evaluation of HT was performed after final imaging for comparison with magnetic resonance imaging results.
RESULTS: Final hemorrhage scores based on severity were as follows: HI-1 23.1%, HI-2 30.8%, PH-1 30.8%, and PH-2 15.4%. Similar to clinical observations, only PH-2 was associated with neurologic deterioration and associated weight loss.
CONCLUSIONS: This model has a high incidence of parenchymal hematomas (46.2%) and therefore is appropriate for the evaluation of novel therapeutics targeting blood-brain barrier integrity and the reduction of symptomatic HT events (PH-2), as well as those potentially "at risk" for neurologic deterioration (PH-1).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757286      PMCID: PMC5138858          DOI: 10.1161/STROKEAHA.108.520304

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  32 in total

1.  Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator.

Authors:  S C Fagan; J H Garcia
Journal:  Pharmacotherapy       Date:  1999-02       Impact factor: 4.705

2.  Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.

Authors:  Götz Thomalla; Jan Sobesky; Martin Köhrmann; Jochen B Fiebach; Jens Fiehler; Olivier Zaro Weber; Anna Kruetzelmann; Thomas Kucinski; Michael Rosenkranz; Joachim Röther; Peter D Schellinger
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

3.  Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model.

Authors:  S A Menzies; J T Hoff; A L Betz
Journal:  Neurosurgery       Date:  1992-07       Impact factor: 4.654

4.  Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction.

Authors:  M FISHER; R D ADAMS
Journal:  J Neuropathol Exp Neurol       Date:  1951-01       Impact factor: 3.685

5.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

6.  Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain.

Authors:  C Neumann-Haefelin; G Brinker; U Uhlenküken; F Pillekamp; K-A Hossmann; M Hoehn
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.

Authors:  D E Levy; T G Brott; E C Haley; J R Marler; G L Sheppard; W Barsan; J P Broderick
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

View more
  13 in total

1.  Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion.

Authors:  Max Nedelmann; Nouha Ritschel; Simone Doenges; Alexander C Langheinrich; Till Acker; Peter Reuter; Mesut Yeniguen; Jan Pukropski; Manfred Kaps; Clemens Mueller; Georg Bachmann; Tibo Gerriets
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

2.  Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats.

Authors:  Gang Wu; Xuhui Bao; Guohua Xi; Richard F Keep; B Gregory Thompson; Ya Hua
Journal:  J Neurosurg       Date:  2011-02-04       Impact factor: 5.115

3.  Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke.

Authors:  Ayush Batra; Lawrence L Latour; Christl A Ruetzler; John M Hallenbeck; Maria Spatz; Steven Warach; Erica C Henning
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-03       Impact factor: 6.200

Review 4.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

Review 5.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

6.  Blood-brain barrier disruption after cardiac surgery.

Authors:  J G Merino; L L Latour; A Tso; K Y Lee; D W Kang; L A Davis; R M Lazar; K A Horvath; P J Corso; S Warach
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-23       Impact factor: 3.825

Review 7.  Recommendations for preclinical research in hemorrhagic transformation.

Authors:  Susan C Fagan; Paul A Lapchak; David S Liebeskind; Tauheed Ishrat; Adviye Ergul
Journal:  Transl Stroke Res       Date:  2013-06       Impact factor: 6.829

Review 8.  Standards and pitfalls of focal ischemia models in spontaneously hypertensive rats: with a systematic review of recent articles.

Authors:  Hiroshi Yao; Toru Nabika
Journal:  J Transl Med       Date:  2012-07-06       Impact factor: 5.531

9.  Mixed cerebrovascular disease and the future of stroke prevention.

Authors:  Mark Fisher; Vitaly Vasilevko; David H Cribbs
Journal:  Transl Stroke Res       Date:  2012-05-04       Impact factor: 6.829

10.  Blood brain barrier breakdown as the starting point of cerebral small vessel disease? - New insights from a rat model.

Authors:  Stefanie Schreiber; Celine Zoe Bueche; Cornelia Garz; Holger Braun
Journal:  Exp Transl Stroke Med       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.